Infliximab: Use in Inflammatory Bowel Disease

Area of Science:

• Immunology
• Gastroenterology
• Pharmacology

Background:

• Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic conditions lacking a cure, often necessitating surgical intervention.
• Traditional therapies for IBD have limitations, driving the development of targeted biologic agents.
• Understanding the immune pathways involved in IBD has led to novel therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy and role of infliximab, a biologic therapy, in managing inflammatory bowel diseases.
• To highlight infliximab's impact on inducing and maintaining remission in Crohn's disease and its potential in ulcerative colitis.
• To discuss infliximab's utility as a steroid-sparing agent and for extraintestinal manifestations of IBD.

Main Methods:

• Review of clinical data and studies on infliximab use in IBD patients.
• Analysis of infliximab's mechanism of action targeting tumor necrosis factor-alpha (TNF-alpha).
• Assessment of infliximab's efficacy in inducing short-term remission and providing long-term maintenance of remission.

Main Results:

• Infliximab demonstrates superior efficacy compared to traditional agents, rapidly inducing remission in CD.
• Chronic infliximab therapy provides sustained remission maintenance.
• Evidence supports infliximab's use as a steroid-sparing agent and for extraintestinal manifestations, with emerging data for UC.

Conclusions:

• Infliximab is a clinically effective and cost-effective biologic therapy that has revolutionized IBD treatment.
• While requiring careful monitoring for rare toxicities, infliximab can modify disease course, prevent complications, and reduce surgical needs in IBD.
• Ongoing development of biologic agents holds promise for further improving IBD management and patient outcomes.